MIT dataset expansion quantities and Proportions. by Chao Tang (10925)

Experimental hardware and software environment. by Chao Tang (10925)

PCA-CGAN K-fold experiment table. by Chao Tang (10925)

Classification model parameter settings. by Chao Tang (10925)

MIT-BIH expanded dataset proportion chart. by Chao Tang (10925)

AUROC Graphs of RF Model and ResNet. by Chao Tang (10925)

PCA-CGAN Model Workflow Diagram. by Chao Tang (10925)

Structural Diagrams of RF Model and ResNet Model. by Chao Tang (10925)

PCA-CGAN model convergence curve. by Chao Tang (10925)

PCA-CGAN Structure Diagram. by Chao Tang (10925)

Comparison of Model Five-classification Results. by Chao Tang (10925)

PCAECG-GAN K-fold experiment table. by Chao Tang (10925)

PCA-CGAN Pseudocode Table. by Chao Tang (10925)

PCA-CGAN Ablation Experiment Results. by Chao Tang (10925)

Supporting datasets for all figures. by Matthew Drill (22258391)

“…Inhibition of P2X7R with small molecule antagonist AZ10606120, for 72 hours significantly decreased U251 cell number (p < 0.0001), and significantly increased tumour cell death, as evidenced by increased LDH release (p < 0.001). …”

Data Sheet 1_Prevalence of fungal colonization among patients with psoriasis in difficult-to-treat areas: impact of apremilast on mycotic burden and clinical outcomes.pdf by Elena Campione (8906858)

“…Finally, improvements in clinical scores i.e., PASI, NAPSI, DLQI, itch VAS, PAIN VAS, scPGA and sPGA-G and biochemical serum profile, as well as a significant decrease in serum IL-17A, TGF-β 1 and IL-10 levels (from 8.51 to 4.16 pg/mL; from 66.10 to 48.70 ng/mL and from 20.05 to 14 pg/mL, respectively) were observed in all patients.…”

Table 2_Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients.docx by Roberta Belli (6939221)

“…Finally, treatment with anti-IL-23 led to a reduction in visfatin levels in female psoriatic patients and resulted in a significant decrease in fat mass percentage in men. …”

Table 1_Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients.docx by Roberta Belli (6939221)

“…Finally, treatment with anti-IL-23 led to a reduction in visfatin levels in female psoriatic patients and resulted in a significant decrease in fat mass percentage in men. …”

Table 3_Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients.docx by Roberta Belli (6939221)

“…Finally, treatment with anti-IL-23 led to a reduction in visfatin levels in female psoriatic patients and resulted in a significant decrease in fat mass percentage in men. …”

Image 1_Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients.jpg by Roberta Belli (6939221)

“…Finally, treatment with anti-IL-23 led to a reduction in visfatin levels in female psoriatic patients and resulted in a significant decrease in fat mass percentage in men. …”